Myokardia Inc (MYOK) Insider Sells $225,000.00 in Stock

Myokardia Inc (NASDAQ:MYOK) insider Jake Bauer sold 5,000 shares of the company’s stock in a transaction that occurred on Tuesday, January 9th. The shares were sold at an average price of $45.00, for a total value of $225,000.00. Following the completion of the transaction, the insider now owns 56,777 shares in the company, valued at $2,554,965. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Jake Bauer also recently made the following trade(s):

  • On Tuesday, January 2nd, Jake Bauer sold 5,000 shares of Myokardia stock. The shares were sold at an average price of $42.89, for a total value of $214,450.00.

Myokardia Inc (NASDAQ MYOK) opened at $52.90 on Friday. Myokardia Inc has a 52 week low of $10.55 and a 52 week high of $53.25. The company has a market capitalization of $1,772.76, a price-to-earnings ratio of -69.60 and a beta of 4.21.

Myokardia (NASDAQ:MYOK) last released its quarterly earnings results on Thursday, November 2nd. The biotechnology company reported ($0.42) EPS for the quarter, hitting analysts’ consensus estimates of ($0.42). Myokardia had a negative return on equity of 14.92% and a negative net margin of 53.49%. The company had revenue of $5.63 million for the quarter, compared to analysts’ expectations of $6.10 million. During the same period in the prior year, the firm earned ($0.35) earnings per share. The firm’s revenue was up 58.6% compared to the same quarter last year. research analysts forecast that Myokardia Inc will post -1.62 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Myokardia by 11.5% during the second quarter. Vanguard Group Inc. now owns 764,919 shares of the biotechnology company’s stock worth $10,020,000 after purchasing an additional 78,800 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in Myokardia by 103.5% during the second quarter. JPMorgan Chase & Co. now owns 476,575 shares of the biotechnology company’s stock worth $6,243,000 after purchasing an additional 242,408 shares in the last quarter. Wells Fargo & Company MN lifted its stake in Myokardia by 2,151.7% during the third quarter. Wells Fargo & Company MN now owns 417,439 shares of the biotechnology company’s stock worth $17,887,000 after purchasing an additional 398,900 shares in the last quarter. VHCP Management II LLC purchased a new stake in shares of Myokardia during the third quarter worth $11,355,000. Finally, RTW Investments LP purchased a new stake in shares of Myokardia during the third quarter worth $10,882,000. Institutional investors own 63.61% of the company’s stock.

MYOK has been the topic of a number of recent analyst reports. Zacks Investment Research cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, October 11th. Credit Suisse Group reiterated an “outperform” rating and issued a $55.00 price objective (up from $45.00) on shares of Myokardia in a report on Tuesday, September 19th. TheStreet cut Myokardia from a “c” rating to a “d+” rating in a report on Friday, November 3rd. JPMorgan Chase & Co. initiated coverage on Myokardia in a report on Tuesday, December 12th. They issued an “overweight” rating and a $54.00 price objective on the stock. Finally, BidaskClub cut Myokardia from a “hold” rating to a “sell” rating in a report on Wednesday, December 20th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. Myokardia has an average rating of “Hold” and an average price target of $54.83.

TRADEMARK VIOLATION WARNING: This piece was originally published by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://ledgergazette.com/2018/01/13/myokardia-inc-myok-insider-sells-225000-00-in-stock.html.

Myokardia Company Profile

MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.

Insider Buying and Selling by Quarter for Myokardia (NASDAQ:MYOK)

Receive News & Ratings for Myokardia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myokardia and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply